Pipeline and Status

The chart below illustrates the status of SAJE’s pipeline programs for the drugs and disease models that have been completed to date. SPL-334 is also being studied in other animal models of disease with results available in the near future. Other drug candidates are being synthesized and tested in various models of disease using many routes of administration with accompanying PK/PD studies.

Drug Candidate GSNOR Inhibition In Vitro Indication Route Animal Studies In Vivo
SPL-334.1 + IPF
Asthma
Inflammation
Oral
Oral
Oral
+
+
+
SPL-227.1 + Inflammation Oral? +
SPL-875.1 + Inflammation
Cardiovascular
Oral? +
SPL-891.1 + Inflammation
IPF
NASH
Cancer
Aging
RA
Oral +